APRN Ebook Continuing Education

• Boland, R., & Verduin, M. (2022). Substance use and addictive disorders. In Kaplan & Saddock’s synopsis of psychiatry (12th Ed.). Wolters Kluwer • Bounds C & Nelson, V. (2022). Benzodiazepines. StatPearls, https://www.ncbi.nlm.nih.gov/ books/NBK470159/#_NBK470159_pubdet_ • Brannon, G. (2019). Inhalant related psychiatric disorders; Medscape Drugs & Diseases https://emedicine.medscape.com/article/290344-overview • Broderick, S. (2023). What does vaping do to your lungs? Health, Johns Hopkins University, https://www.hopkinsmedicine.org/health/wellness-and-prevention/what-does-vaping-do- to-your-lungs • Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022). Novel agents for the pharmacological treatment of alcohol use disorder. Drugs, 82(3), 251-274. https://doi.org/10.1007/s40265-021-01670-3 • Carlat Addiction Treatment Report. (2019). Primer: Physical examination in addiction practice. https://www.thecarlatreport.com/articles/3050-primer-physical-examination-in- addiction-practice • Centers for Disease Control and Prevention (CDC). (2022a). About CDC’s opioid prescribing guideline. https://www.cdc.gov/opioids/providers/prescribing/guideline.html • Centers for Disease Control and Prevention (CDC). (2022b). Provisional drug overdose death counts. https://www.cdc.gov/media/releases/2022/s0210-prescribing-opioids.html • Centers for Disease Control and Prevention (CDC). (2021). Understanding the epidemic. https://www.cdc.gov/drugoverdose/epidemic/index.html • Centers for Disease Control and Prevention. (2019). CDC updates EVALI guidance for health care providers as flu activity increases nationally. https://www.cdc.gov/media/releases/2019/ p1119-evali-guidance.html • Ciraulo, D. (2014). Sedative, hypnotic, or anxiolytic related disorders. In Gabbard, G. (Ed). Treatment of psychiatric disorders (5th Ed). American Psychiatric Association. • Cohen, S. P., Vase, L., & Hooten, W. M. (2021). Chronic pain: An update on burden, best practices, and new advances. The Lancet, 397(10289), P2082-2097. https://doi.org/10.1016/ S0140-6736(21)00393-7 • Council of State and Territorial Epidemiologists HAI Subcommittee, Drug Diversion Workgroup. (2019). Healthcare-associated infections, drug diversion planning, and response toolkit for state and local health departments. https://cdn.ymaws.com/www.cste.org/ resource/resmgr/pdfs/pdfs2/Drug_Diversion_Toolkit_LiveL.pdf • DeBar, L., Mayhew, M., Benes, L., Bonifay, A., Deyo, R.A., Elder, C. R., Keefe, F. J., Leo, M. C., McMullen, C., Owen-Smith, A., Smith, D. H., Trinacty, C. M., & Vollmer, W. M. (2022). A primary care–based cognitive behavioral therapy intervention for long-term opioid users with chronic pain: A randomized pragmatic trial. Annals of Internal Medicine. https://doi. org/10.7326/M21-1436 • Dowell, D. Ragan, K., Jones, C., Baldwin, G., & Chou, R. (2022). CDC clinical practice guideline for prescribing opioids for pain—United States. MMWR Recommendations and Reports 71(No. RR-3), 1-95. https://doi.org/10.15585/mmwr.rr7103a1 • Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain: United States. MMWR Recommendations and Reports, 65(RR-1), 1-49. http:// dx.doi.org/10.15585/mmwr.rr6501e1 • Drugs.com (2022). Acamprosate. https://www.drugs.com/acamprosate.html • Edinoff, A. N., Nix, C. A., Hollier, J., Sagrera, C. E., Delacroix, B. M., Abubakar, T., Cornett, E. M., Kaye, A. M., & Kaye, A. D. (2021). Benzodiazepines: Uses, Dangers, and Clinical Considerations. Neurology international, 13(4), 594–607. https://doi.org/10.3390/ neurolint13040059 • Erlach, S. (2022). Sedative, Hypnotic, Anxiolytic use disorders clinical presentation, Medscape Drugs & Diseases https://emedicine.medscape.com/article/290585-clinical • Forrest, J. (2020). Hallucinogen Use. Medscape Drugs and Diseases https://emedicine. medscape.com/article/293752-overview • Halpape, K., Jorgenson, D., Ahmed, A., Kizlyk, K., Landry, E., Marwah, R., Raiche, T., & Wiebe, A. (2022). Pharmacist-led strategy to address the opioid crisis: The Medication Assessment Centre Interprofessional Opioid Pain Service (MAC iOPS). Canadian Pharmacists Journal/Revue Des Pharmaciens Du Canada, 155(1), 21-25. https://doi. org/10.1177/17151635211045950 • Hayden, J. A., Ellis, J., Ogilvie, R., Malmivaara, A., & van Tulder, M. W. (2021). Exercise therapy for chronic low back pain. Cochrane Database of Systematic Reviews, 9(CD009790). https://doi.org/10.1002/14651858.CD009790.pub2 • Hoffman, R. S., & Weinhouse, G. L. (2023). Management of moderate and severe alcohol withdrawal syndromes. UpToDate. https://www.uptodate.com/contents/management-of- moderate-and-severe-alcohol-withdrawal-syndromes • Holstege, C. P., Zhong, Q. X., Tiouririne, N. A., Holian, A. H., & Borek, H. A. (2021). Cocaine- related psychiatric disorders. Medscape Reference. https://emedicine.medscape.com/ article/290195-overview • Jones, C. M., Compton, W. M., & Mustaquim, D. (2020). Patterns and characteristics of methamphetamine use among adults — United States, 2015–2018. MMWR. Morbidity and Mortality Weekly Report, 69(12), 317-323. https://doi.org/10.15585/mmwr.mm6912a1 • Kene, M., Bhopale, S., Eaton, A., Awsare, S. V., & Reed, M. E. (2022). Opioid safety initiative associated with decreased emergency department opioid prescribing. The American Journal of Managed Care, 28(6), e203-e211. https://doi.org/10.37765/ajmc.2022.89158 • Kreitzer, M. J., & Koithan, M. (2019). Integrative nursing (2nd ed.). Oxford University Press • Kroenke, K., Alford, D. P., Argoff, C., Canlas, B., Covington, E., Frank, J. W., Haake, K. J., Hanling, S.Hooten, W. M., Kertesz, S. G., Kravitz, R. L., Krebs, E. E., Stanos, S. P., & Sullivan, M. (2019). Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: A Consensus Panel report. Pain Medicine, 20(4), 724-735. https://doi. org/10.1093/pm/pny307 • Lande, R. (2018). Nicotine Addiction, Medscape Drugs and Diseases https://emedicine. medscape.com/article/287555-overview#a2 • Marel, C., Sunderland, M., Mills, K. L., Slade, T., Teesson, M., & Chapman, C. (2019). Conditional probabilities of substance use disorders and associated risk factors: Progression from first use to use disorder on alcohol, cannabis, stimulants, sedatives and opioids. Drug and alcohol dependence, 194, 136–142. https://doi.org/10.1016/j.drugalcdep.2018.10.010 • Mariani, J. (2013). Alcohol related disorders (5th Ed). In Gabbard, G. (Ed). Treatment of psychiatric disorders (5th Ed). American Psychiatric Association. • Mihic S, & Mayfield J (2023). Hypnotics and sedatives. Brunton L.L., & Knollmann B.C.(Eds.), Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 14e. McGraw Hill. https://accessmedicine.mhmedical.com/content.aspx?bookid=3191&section id=269719266 • Moe, F., Moltu, C., McKay, J., Nesvag, S., Bjornestad, J. (2022). Is the relapse concept in studies of substance use disorders a ‘one size fits all concept? A systematic review of relapse operationalisations. Drug and Alcohol Review (41), 743-758. • https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/dar.13401 • National Association of Drug Diversion Investigators. (2021). Institutional Drug Diversion Toolkit. https://www.naddi.org/wp-content/uploads/2017/08/NADDI-Institutional-Drug- Diversion-Toolkit-v2.pdf • National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2023). Alcohol use in the United States: Age groups and demographic characteristics. https://www.niaaa.nih.gov/ alcohols-effects-health/alcohol-topics/alcohol-facts-and-statistics/alcohol-use-united-states- age-groups-and-demographic-characteristics • National Institute on Alcohol Abuse and Alcoholism (NIAAA). (2021). The cycle of alcohol addiction. https://www.niaaa.nih.gov/publications/cycle-alcohol-addiction • National Institute on Drug Abuse (NIDA). (2018). Understanding drug use and addiction. DrugFacts. https://nida.nih.gov/publications/drugfacts/understanding-drug-use-addiction was 2022b • National Institute on Drug Abuse (NIDA). (2020a). Commonly used drugs charts. National Institute on Drug Abuse. https://nida.nih.gov/research-topics/commonly-used-drugs- charts#ketamine • National Institute on Drug Abuse (NIDA). (2020b). Drugs and the brain. https://nida.nih.gov/ publications/drugs-brains-behavior-science-addiction/drugs-brain was 2022a • National Conference of State Legislatures (NCSL). (2019). Prescribing policies: States confront opioid overdose epidemic. https://www.ncsl.org/research/health/prescribing- policies-states-confront-opioid-overdose-epidemic.aspx • National Council State Boards of Nursing (NCSBN). (2018a). A Nurse Manager’s Guide to Substance Use Disorder in Nursing. https://ncsbn.org/public-files/Mgr_SUDiN_ Brochure_2014.pdf • National Council State Boards of Nursing (NCSBN). (2018b). What You Need to Know About Substance Use Disorder in Nursing. https://ncsbn.org/public-files/SUD_Brochure_2014.pdf

• Norcross, J. C., Beutler, L. E., & Goldfried, M. R. (2019). Cognitive-behavioral therapy and psychotherapy integration. In K. S. Dobson & D. J. A. Dozois (Eds.), Handbook of cognitive- behavioral therapies (pp. 318–345). The Guilford Press. • Nyhus, J. (2021). Drug diversion in healthcare. American Nurse Journal, online. https://www. myamericannurse.com/drug-diversion-in-healthcare/ • Pak, D. J., Yong, R. J., Kaye, A. D., & Urman, R. D. (2018). Chronification of pain: Mechanisms, current understanding, and clinical implications. Current Pain and Headache Reports, 22(2), 9. https://doi.org/10.1007/s11916-018-0666-8; PMID: 29404791 • Paxos, C. & Teter, C. (2019). Substance-related disorders. In M. Burns, T. Schwinghammer, P. Malone, J. Kolesar, K. Lee, & P. Bookstaver (Eds.), Pharmacotherapy: Principles and practice. (pp. 547-562). McGraw Hill Education. • Pino, C. A., & Wakeman, S. E. (2022). Prescription of opioids for acute pain in opioid naïve patients. UpToDate. https://www.uptodate.com/contents/prescription-of-opioids-for-acute- pain-in-opioid-naive-patients • Preda, A. (2018). Stimulants. Medscape Drugs and Diseases https://emedicine.medscape. com/article/289007-overview • PsychDB (2021). Benzodiazepines, https://www.psychdb.com/teaching/clinical-practice- guidelines-cpg#benzodiazepines • Raihan, N., & Cogburn, M. (2022). Stages of change theory. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK556005/ • Richards, J. R., & Laurin., E. G. (2022). Methamphetamine toxicity. National Library of Medicine. https://www.ncbi.nlm.nih.gov/books/NBK430895/ • Riva, J. J., Noor, S. T., Wang, L., Ashoorion, V., Foroutan, F., Sadeghirad, B., Couban, R., & Busse, J. W. (2020). Predictors of prolonged opioid use after initial prescription for acute musculoskeletal injuries in adults: A systematic review and meta-analysis of observational studies. Annals of Internal Medicine. https://doi.org/10.7326/M19-3600 • Robinson, A., Wilson, M. N., Hayden, J. A., Rhodes, E., Campbell, S., MacDougall, P., & Asbridge, M. (2021). Health care provider utilization of prescription monitoring programs: A systematic review and meta-analysis. Pain Medication, 22(7), 1570-1582. https://doi. org/10.1093/pm/pnaa412 • SB63. (2021). Missouri Senate modifies provisions relating to the monitoring of certain controlled substances. https://www.senate.mo.gov/21info/BTS_Web/Bill.aspx?SessionType =R&BillID=54228843Smith, T., & Hillner, B. (2019). The cost of pain. JAMA Network Open, 2(4), e191532. https://doi.org/10.1001/jamanetworkopen.2019.1532 • Singh,D. & Saadabadi, A. (2022). Naltrexone. StatPearls. https://www.ncbi.nlm.nih.gov/ books/NBK534811/?report=reader#_NBK534811_pubdet_ • Smith, T. J., & Hillner, B. E. (2019). The cost of pain. JAMA Network Open, 2(4), e191532. doi: 10.1001/jamanetworkopen.2019.1532 • Stanford College of Medicine. (2022). Opioid equianalgesic table. https://palliative.stanford. edu/opioid-conversion/equivalency-table/ • Stahl, S. (2020). Stahl’s essential psychopharmacology: Neuroscientific basis and practical applications (4th Ed). Cambridge University Press • Stokes, M. & Abdijadid, S. (2022). Disulfiram. StatPearls. https://www.ncbi.nlm.nih.gov/ books/NBK459340/#_NBK459340_pubdet_ • Substance Abuse and Mental Health Services Administration (SAMHSA). (2022a). Medication-assisted treatment (MAT). https://www.samhsa.gov/medication-assisted- treatment • Substance Abuse and Mental Health Services Administration (SAMHSA). (2022b). Statutes, regulations, and guidelines. https://www.samhsa.gov/medication-assisted-treatment/ statutes-regulations-guidelines • Substance Abuse and Mental Health Services Administration (SAMHSA). (2022c). Become a buprenorphine waivered practitioner. https://www.samhsa.gov/medication-assisted- treatment/become-buprenorphine-waivered-practitioner • Substance Abuse and Mental Health Services Administration (SAMHSA). (2020). Treatment of Stimulant Use Disorders. https://store.samhsa.gov/sites/default/files/pep20-06-01-001. pdf • Substance Abuse and Mental Health Services Administration. (2018). SAMHSA opioid overdose prevention toolkit. HHS Publication No. (SMA) 18 - 4742. https://store.samhsa.gov/ system/files/sma18-4742.pdf • SureScripts. (2022a). Electronic prescribing for controlled substances: 20 years of persistence and progress. https://surescripts.com/news-center/intelligence-in-action/opioids/electronic- prescribing-for-controlled-substances-20-years-of-persistence-and-progress • SureScripts. (2022b). Scripts Network Alliance: 2021 national progress report. https:// surescripts.com/docs/default-source/national-progress-reports/2021-national-progress- report.pdf?sfvrsn=71fcbe15_14 • Tori, M. E., Larochelle, M. R., & Naimi, T.S. (2020). Alcohol or benzodiazepine co- involvement with opioid overdose deaths in the United States. JAMA Network Open, 3(4), e202361. https://doi.org/10.1001/jamanetworkopen.2020.2361 • The University of Michigan. (2022). Michigan open. https://opioidprescribing.info/ • U.S. Department of Health and Human Services (HHS). (2019a). Indian Health Services: Pain management. https://www.ihs.gov/painmanagement/treatmentplanning/informedconsent/ • U.S. Department of Health and Human Services (HHS). (2019b). Pain Management Best Practices Inter-Agency Task Force Report: Updates, gaps, inconsistencies, and recommendations. https://www.hhs.gov/opioids/prevention/pain-management-options/ index.html • U.S. Department of Health & Human Services. (HHS). (2016). Facing addiction in America: The Surgeon General’s report on alcohol, drugs, and health. https://addiction. surgeongeneral.gov/sites/default/files/surgeon-generals-report.pdf • U.S. Drug Enforcement Agency (DEA). (2020a). Drugs of abuse: A DEA resource guide. https://www.dea.gov/sites/default/files/2020-04/Drugs%20of%20Abuse%202020-Web%20 Version-508%20compliant-4-24-20_0.pdf • U.S. Drug Enforcement Agency (DEA). (2022). Mid-level practitioners authorization by state. https://www.deadiversion.usdoj.gov/drugreg/practioners/index.html • U.S. Drug Enforcement Agency (DEA) (2018a). The Controlled Substances Act. https://www. dea.gov/drug-information/csa • U.S. Drug Enforcement Agency (DEA). (2018b). Drug policy. https://www.dea.gov/drug- information/drug-policy • U.S. Drug Enforcement Agency (DEA). (2010a). Electronic prescriptions for controlled substances (EPCS). https://www.deadiversion.usdoj.gov/ecomm/e_rx/index.html • U.S. Drug Enforcement Agency (DEA). (2010b). Role of authorized agents in communicating controlled substance prescriptions to pharmacies. https://www.deadiversion.usdoj.gov/ fed_regs/rules/2010/fr1006.htm • U.S. Food and Drug Administration (FDA). (2022a). FDA restricts prescription codeine pain and cough medicines and tramadol pain medicines in children; recommends against use in breastfeeding women. https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-drug- safety-podcast-fda-restricts-use-prescription-codeine-pain-and-cough-medicines-and- tramadol • U.S. Food and Drug Administration (FDA). (2022b). FDA Urges caution about withholding opioid addiction medications from patients taking benzodiazepines or CNS depressants: Careful medication management can reduce risks. https://www.fda.gov/drugs/fda-drug- safety-podcasts/fda-drug-safety-podcast-fda-urges-caution-about-withholding-opioid- addiction-medications-patients • U.S. Food and Drug Administration (FDA). (2021). Approved Risk Evaluation and Mitigation Strategies (REMS). https://www.accessdata.fda.gov/scripts/cder/rems/index. cfm?event=RemsDetails.page&REMS=17 • U.S. Food and Drug Administration (FDA). (2018). FDA education blueprint for health care providers involved in treating and monitoring patients with pain. https://www.fda.gov/ media/99496/download • Walters M (2021). Using SBIRT for substance use relapse. Nursing. 2021 (3). 63-66. doi: 10.1097/01.NURSE.0000724424.00301.19. PMID: 33674539. Werner et al., 2020 • Wise, R. Jordan, C. (2021). Dopamine, behavior, and addiction. Journal of Biomedical Science (28), 83. https://doi.org/10.1186/s12929-021-00779-7 • Wolfe, H. L., Biello, K. B., Reisner, S. L., Mimiaga, M. J., Cahill, S. R., & Hughto, J. M. W. (2021). Transgender-related discrimination and substance use, substance use disorder diagnosis and treatment history among transgender adults. Drug and alcohol dependence, 223, 108711. https://doi.org/10.1016/j.drugalcdep.2021.108711

EliteLearning.com/Nursing

Book Code: AUS3024

Page 31